Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumabYoshinobu Koguchi, William L. Redmond, Noriko Iwamoto et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 20
Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health SystemAlexa K. Dowdell, Brian Piening, Walter J. Urba et al.|JCO Oncology Practice|2024Cited by 11
Clinical impact for advanced non-small-cell lung cancer patients tested using comprehensive genomic profiling at a large USA health care systemRyan Meng, Brian Piening, Alexa K. Dowdell et al.|ESMO Real World Data and Digital Oncology|2024Cited by 4
Improved outcomes from reflex comprehensive genomic profiling-guided precision therapeutic selection across a major US healthcare system.Brian Piening, Carlo Bifulco, Bela Bapat et al.|Journal of Clinical Oncology|2023Cited by 3
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumabYoshinobu Koguchi, William L. Redmond, Noriko Iwamoto et al.|Unknown|2020Cited by 2